Intercept Pharma (ICPT): Symphony Health Indicates Above Consensus Ocaliva Sales - Wedbush

Wedbush analyst, Liana Moussatos, reiterated her Outperform rating on shares of Intercept Pharmaceuticals (NASDAQ: ICPT) and sees growing Ocaliva sales and multiple catalysts in the next 6-18 months.

Symphony Health (SH) estimated just over $5 million for Q3 OCA sales— above consensus of $3.5 million. Based on the monthly estimates for OCA sales for PBC, the analyst estimates Q3 OCA sales of at least $5 million, ahead of the Thomson consensus of ~$3.5 million (range $1.6 million to $7.2 million).

There is no change to estimates at this time since Ocaliva was only launched in June and there is not a consistent capture rate for the Symphony Health monthly estimates compared with reported sales.

No change to the price target of $239.

For an analyst ratings summary and ratings history on Intercept Pharmaceuticals click here. For more ratings news on Intercept Pharmaceuticals click here.

Shares of Intercept Pharmaceuticals closed at $154.00 yesterday.

You May Also Be Interested In

• Craig-Hallum Assumes DiaMedica Therapeutics Inc. (DMAC) at Buy
• SmartFinancial (SMBK) PT Lowered to $24 at Keefe, Bruyette & Woods
• Texas Instruments (TXN) PT Raised to $175 at TD Cowen